UBE2J2

Across TCGA pan-cancer cohorts, UBE2J2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UBE2J2 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher UBE2J2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2J2 expression acts as an unfavorable survival marker.

BRCA, LUSC, and MESO are the cancer types where UBE2J2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.300	0.924	<.001	36	view →
LUSC	OS	Median	III,IV	0.126	0.664	.008	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

UBE2J2–BRCA (OS)

Open the BRCA breakdown →